Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market
* Seegene announces partnership with Bio-Rad for the development and commercialization of infectious disease molecular diagnostic products * Diagnostic tests designed for the pandemic and the post-pandemic era with high multiplex technology * A significant step forward for Seegene in expandi...
Seegene unveils "MOBILE STATION," for on-site routine testing at public-use facilities and communities
* Seegene unveils "MOBILE STATION" at the Medlab Middle East 2021 * Mobile laboratory designed for mass testing at schools, airports, or communities, delivering test results within 3h 30min with the maximum testing capacity of 7,500 a day * The biotechnology firm to sign an MOU with G42 Heal...
Seegene reports solid results in the first quarter of 2021 with KRW 351.8 billion
* SEEGENE POSTS KRW 193.9 BIL. IN OPERATING PROFIT, UP 388% ON-YEAR * OPERATING PROFIT RATIO AT 55%, DESPITE CONSTANT INVESTMENT IN R&D AND EMPLOYEES SEOUL, South Korea, May 25, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a molecular diagnostics company reported its financial results for th...
Seegene introduces an exclusive diagnostic system for diagnosing COVID-19 variants at ECCMID
SEOUL, Korea, May 24, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a biotechnology firm specializing in molecular diagnostics has once again been recognized for its unique system for diagnosing COVID-19 variants at this year's European Congress of Clinical Microbiology, the ECCMID. Seegene's...
/DISREGARD RELEASE: Seegene Inc./
We are advised by Seegene Inc. that journalists and other readers should disregard the news release, Seegene reports solid results in the first quarter of 2021 withKRW 351.8 billion, issued 12-May-2021 over PR Newswire....
Seegene's Germany subsidiary supports the back-to-school initiative with its COVID-19 tests
* SEEGENE BACKS GERMANY IN ITS EFFORT TO RETURN TO NORMALCY * GERMAN SUBSIDIARY TO SUPPLY COVID-19 DIAGNOSTIC TESTS ENOUGH TO TEST 734,000 PUPILS SEOUL, South Korea, May 11, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading molecular diagnostics firm said its German subsidiary, Seegene...
Seegene to supply COVID-19 diagnostic tests worth 16 mil. GBP to Scotland, triple the sales volume seen last year
* Second public procurement agreement after Italy's procurement deal worth EUR 89.3 million SEOUL, South Korea, April 22, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm said it began supplying its COVID-19 diagnostic tests worth16,209,150 GBP to Scotland under a pub...
Seegene's Italy subsidiary secures public procurement for 7.15 million COVID-19 diagnostic tests, the largest tender in history
* Seegene's Italian subsidiary to supply some 7.15 million COVID-19 tests to 17 regions there * S. Korean biotechnology firm to expand its influence in Italy's PCR diagnostic industry SEOUL, South Korea, April 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading molecular diagnostics ...
Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic
* Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month SEOUL, South Korea, April 12, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a biotechnology company specializing in molecular diagnostics, announced today that it has secured an export ...
Seegene supports Mexico's 'back to school' campaign with COVID-19 tests and face masks
SEOUL, South Korea, April 9, 2021 /PRNewswire/ -- South Korea's leading
molecular diagnostics firm Seegene Inc. (KQ096530) said Friday it is supporting
the Mexican government's push to return life to pre-pandemic days.
Seegene's Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants
* Seegene's new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 minutes * Seegene's proprietary high multiplex technology enables detection of 10 different targets * S. Korean firm to research additional versions of variant diagnostic tests SEOUL, South Korea,...
Seegene posts unprecedented Q4 and 2020 FY results; writes history by joining trillion-won club
SEOUL, South Korea, Feb.18, 2021 /PRNewswire/ -- South Korea's leading molecular diagnostics firm Seegene Inc. (KQ096530) reported preliminary financial results for the fourth quarter and the fiscal year of 2020, showing records never seen before. The company postedKRW 441.7 billion in consolidat...
Seegene's saliva test for COVID-19 is just as effective as NPS test
SEOUL, South Korea, Feb.18, 2021 /PRNewswire/ -- A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen. A research team at the Department of Laboratory Medicine at Kangwon National University School of Medicine,...
Seegene develops world first COVID-19 variant test capable of identifying origins of virus variants
* SEEGENE ROLLS OUT FIRST COVID-19 MUTANT IDENTIFICATION TEST * COVID-19 TEST MANUFACTURER CONTINUES TRACKING VARIANTS * S. KOREAN FIRM COMMITTED TO WORKING WITH GOVERNMENTS SEOUL, South Korea, Feb. 1, 2021 /PRNewswire/ -- South Korea's biotechnology firm Seegene (KQ096530) said Monday it ...
Seegene to advance business in Latin America in the New Year
SEOUL, South Korea, Jan. 21, 2021 /PRNewswire/ -- South Korea's leading molecular diagnostics firm Seegene Inc. (KQ096530) said Wednesday that it is expanding its business inLatin America in the new year with a strong focus on its multiplex assay product. Seegene said it received an approval f...
Seegene's COVID-19 test with saliva sample collection feature now available in Europe
SEOUL, South Korea, Jan. 6, 2021 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2 Assay and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay...
Seegene's COVID-19 test with saliva sample collection feature now available in Europe
SEOUL, South Korea, Jan. 6, 2021 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Tuesday that it has CE-IVD marked the saliva-based testing application for Allplex™ SARS-CoV-2 Assay and Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay...
Seegene donates 20,000 COVID-19 tests to Ecuador
SEOUL, South Korea, Dec. 17, 2020 /PRNewswire/ -- Seegene Inc. (KQ096530), a South Korean biotechnology company specializing in molecular diagnostics says it has donated 20,000 COVID-19 tests (Allplex™ SARS-CoV-2 Assay) to Ecuadorian government to help fight the COVID-19 pandemic together. The So...
Seegene's aggregated sales surpass KRW 1 tril. this year and plans on expanding annual production capacity to KRW 5 tril. in 2021
SEOUL, South Korea, Dec. 13, 2020 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnosis, Seegene Inc. (KQ096530), announced Monday that its aggregated sales this year have already surpassed theKRW 1 trillion mark, up nearly 10 times its previous annual sales of K...
Seegene's COVID-19/FluA,B/RSV test with extraction-free feature now available in Europe
SEOUL, South Korea, Dec. 3, 2020 /PRNewswire/ -- South Korea's biotechnology company specializing in molecular diagnostics, Seegene Inc. (KQ096530) said Thursday that the extraction-free application of Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is now available inEurope. Previously in September, Se...
